Jun M, et al. Lancet 2010 Epub May 10

Slides:

Advertisements

Similar presentations

Systematic Review Module 10: Quantitative Synthesis II Thomas Trikalinos, MD, PhD Joseph Lau, MD Tufts EPC.

Advertisements

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Trial profile Fox K et al. Lancet 2008;372:

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

Amarenco P, Labreuche J. Lancet Neurol 2009;8:

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):

The ALERT Trial.

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Baseline Characteristics of the Patients Part I

Copyright © 2012 American Medical Association. All rights reserved.

The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

Scandinavian Simvastatin Survival Study (4S)

What is the likely mechanism by which HDL-C reduces coronary heart disease?

FATS- Familial Atherosclerosis Treatment Study

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

The PPAR Journey: What Can We Expect in the Future?

Diabetes and Dyslipidemia

Figure 6 Differences in glycaemic control with the study drug

Baseline characteristics of patients

Robert W. Yeh et al. JACC 2017;70:

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

Relative risk of major events with atenolol vs placebo

Chen S, Dong Y, Kiuchi MG, et al

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Advances in Hypertriglyceridemia Treatment

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

LDL Cholesterol.

The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis Moritz C. Wyler von Ballmoos, MD, MPH, Bernhard.

Potential mechanisms whereby statins may reduce the risk of stroke

Enrollment and Outcomes

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Berger JS, et al. JAMA 2009;301:

Trial profile Luc F Van Gaal, Lancet 2005;365:1389.

Estimated 5-year rate of a first major vascular event (MVE), major coronary event (MCE),or vascular death in univariate and multivariate risk subgroups.

Volume 375, Issue 9719, Pages (March 2010)

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

New Lipid-Lowering Therapies

Baseline Characteristics of the Study Participants

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Baseline Characteristics by hs-CRP

MATRIX: Radial vs. Femoral

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

Flow chart of search strategy

Adjusted relative risk Adjusted odds ratio

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Independent predictors of all-cause mortality at 30 days.

Presentation transcript:

Jun M, et al. Lancet 2010 Epub May 10

Identification process for eligible studies Jun M, et al. Lancet 2010 Epub May 10

Characteristics of the studies included in the systematic review and meta-analysis – Part I Jun M, et al. Lancet 2010 Epub May 10

Characteristics of the studies included in the systematic review and meta-analysis – Part II Jun M, et al. Lancet 2010 Epub May 10

Effect of fibrates on risk of major cardiovascular outcomes Jun M, et al. Lancet 2010 Epub May 10

Effect of fibrates on the risk of coronary events Jun M, et al. Lancet 2010 Epub May 10

Summary of the relative risks of all outcomes assessed Jun M, et al. Lancet 2010 Epub May 10

Effect of lipid level differences between treatment and placebo groups Jun M, et al. Lancet 2010 Epub May 10

Subgroup analyses for the effects of fibrates on coronary events Jun M, et al. Lancet 2010 Epub May 10

Univariate meta-regression exploring the role of achieved lipid concentrations on the effectiveness of fibrate therapy on coronary events Jun M, et al. Lancet 2010 Epub May 10